Greg Parker graduated from Imperial College, London with a Masters degree in Chemistry and was subsequently awarded his Ph.D. in Organic Chemistry from The University of Bristol before spending time at The Ohio State University on his post-doc. After a brief foray into the world of pharmaceutical patent analysis, Greg returned to his synthetic roots in the area of process R&D. Greg is a recreational stock market enthusiast, focusing in particular on investments for the long-term including dividend and income investing. Greg also has a strong interest in overseas markets, particularly China, as well as in biotech, commodities, oil/gas, and small cap stocks.
I joined Seeking Alpha in February 2014 as editor of the biotech vertical. In addition to onboarding new contributors, my job is to make sure Seeking Alpha provides high-quality and comprehensive coverage of the biotechnology and health care sectors. I am always looking for new ideas, so please reach out if you're interested.
Alex is an equity research analyst at Granite House Capital Management, a value oriented long/short hedge fund based in Boston. In May 2013, Alex was the feature of a Forbes Magazine article titled, "Meet One Of The Youngest And Brightest Hedge Fund Analysts That Isn't On Wall Street." He started investing in the stock market at age 10 and payed for college by working as an analyst for a Minneapolis based hedge fund. He focuses on the investing methods of great investors such as Warren Buffett. Alex looks to differentiate himself in the industry through persistent hard work and continuous learning. He is the youngest ever admitted member of the SumZero buyside network and was one of 14 buyside analysts in nation to be named to the 2012 SumZero Buyside Analyst Honors which was published in the Wall Street Journal as part of the 'Best on the Street' column and CNBC. Over 8,000 analysts were considered and he had the second highest return on the list. He was featured in the biography of investor Warren Buffett in a book called "Of Permanent Value: The Story Of Warren Buffett,". He maintains a blog called "Alex Bossert's Thoughts On Value Investing" with over 550 subscribers and over 300,000 site views. His work has been syndicated on Yahoo Finance, Google Finance, SeekingAlpha, and GuruFocus.
Linkedin Profile: http://www.linkedin.com/in/alexbossert
I work as a Business System Analyst for a global bio-pharmaceutical company based in Illinois. I am a value-investor that looks for opportunities to exploit market inefficiencies to make out sized profits. I generally am interested in the pharmaceutical industry as well as large income producing companies for value investing. Intense research, intelligence, and patience are the keys to having success with this strategy.
My ultimate objective is to leverage the knowledge, experience and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
My focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
I am a professional investment manager and the founder/CEO of Kuma Star Capital, LLC.
My background is in chemistry and materials engineering. My investing specialization is in growth stocks with an emphasis on short-selling, US technology stocks and Chinese ADRs.
I have been in this game for 12 years. Unfortunately (or fortunately) my first adventures were at the top of the tech bubble where for 5 short months I thought I was invincible. I soon found out how "vincible" I was. After the appropriate mourning period I decided that energy/resource stocks were cheap and became invincible again. Margin in an ever rising market made me, once again, "vincible" . I hope to learn.
My investment interests include small and microcap Biotech stocks with a focus on oncology. I worked for several years as a lab manager and research associate at UCSF Cancer Center in a lab focused on sequencing and assembling tumor genomes, array CGH of intermediate grade prostate tumors, and functional analysis of the oncogenic transcription factor ZNF217. During that time I attended as many talks and lectures as time would allow and read as many papers as possible in the course of investigating possible gene targets in regions of interest from aCGH data.
I have BS in biology and a masters degree in Health services administration.